Introduction
============

The European Community Respiratory Health Survey (ECRHS) is a major international study designed to assess lung health in adults. Findings from the first ECRHS showed that prevalence of asthma and allergies as assessed by serum Immunoglobulin E (IgE) were higher in Australia and New Zealand than most European countries.[@b1-copd-11-1097],[@b2-copd-11-1097] In our Melbourne center, the major risk factors for current asthma in young adults were being a female, maternal asthma, smoking, nasal allergies, early respiratory infection, occupational exposures, and atopy.[@b3-copd-11-1097] A follow-up of 5,002 subjects without asthma from 12 centers found that chronic cough and phlegm was an independent predictor of incident chronic obstructive pulmonary disease (COPD), as defined by prebronchodilator spirometry.[@b4-copd-11-1097]

Studies on lung health in adults typically assess both respiratory symptoms and lung function cross-sectionally. Longitudinal follow-up of respiratory symptoms has mostly been conducted in occupational cohorts. A 10-year follow-up of a population-based cohort of adults in rural Canada found that cough, phlegm, and wheeze increased significantly over time.[@b5-copd-11-1097] The Busselton Population Health study in Western Australia found that doctor-diagnosed asthma increased over 16 years accompanied by increased reporting of cough and phlegm, but not wheeze.[@b6-copd-11-1097] The incidence of asthma and respiratory symptoms in adults was related to maternal smoking in Norway,[@b7-copd-11-1097] but only weakly to air pollution in several European centers.[@b8-copd-11-1097]

Lung function has been measured by spirometry in the ECRHS and many other epidemiological studies in adults. It is well known that a high proportion of the cross-sectional variance in lung function is explained by age, sex, height, and ethnicity.[@b9-copd-11-1097],[@b10-copd-11-1097] There are many other risk factors for longitudinal lung function decline (LFD), including tobacco smoking,[@b11-copd-11-1097] occupational exposures,[@b12-copd-11-1097],[@b13-copd-11-1097] asthma,[@b14-copd-11-1097],[@b15-copd-11-1097] and allergies.[@b16-copd-11-1097] Although obesity is associated with adult-onset asthma[@b17-copd-11-1097] and restrictive ventilatory defects, the effect on LFD is uncertain.[@b18-copd-11-1097] Furthermore, the relative contributions of these factors to LFD remains a subject of debate and there are knowledge gaps in this area. Excessively rapid LFD is a well-established precursor of COPD,[@b11-copd-11-1097] airway and systemic inflammation,[@b19-copd-11-1097] hospitalization, and death from COPD.[@b20-copd-11-1097]

Therefore, we investigated the role of these potential risk factors including increase in body mass index (ΔBMI) on LFD using ECRHS data collected on two different occasions from the Melbourne cohort. We specifically asked the following questions: Do changes in symptoms and history of respiratory conditions differ between males and females over 20 years?What are the risk factors for LFD in males and females?

Methods
=======

Subjects
--------

The ECRHS was a multicenter international cohort study of asthma, potential risk factors, and treatment for the disease ([www.ecrhs.org](http://www.ecrhs.org)). The Melbourne center participated in both ECRHS I (November 1992 to April 1994, hereafter referred to as 1993) and ECRHS III (November 2012 to January 2014, referred to as 2013). The sampling strategy has been fully described elsewhere.[@b21-copd-11-1097]

Briefly, for ECRHS I, a random sample of 4,500 adults aged 20--44 years was selected from electoral rolls in Melbourne, Australia. Postal questionnaires were returned by 3,200 subjects.[@b22-copd-11-1097] Subsequently, a sample of 2,042 subjects (including 433 individuals from a symptomatic sample, who reported symptoms suggesting asthma) was invited to complete a comprehensive interviewer-administered main questionnaire and lung function tests. The 876 participants who attended the first survey were reinvited for ECRHS III when 318 completed additional questionnaires and 262 lung function tests. The study was approved by the Human Research Ethics Committees of Monash University and the Alfred Hospital. All participants provided written informed consent.

Questionnaire
-------------

The main questionnaire included validated questions about wheeze, shortness of breath after activity, nocturnal cough, morning sputum, nasal allergies including hay fever, eczema or skin allergies, and cigarette smoking.[@b23-copd-11-1097],[@b24-copd-11-1097] Current asthma was defined as asthma ever confirmed by a doctor and any of the following in the previous 12 months: at least one asthma symptom (wheezing; waking up with chest tightness; shortness of breath at rest during the day, following strenuous activity, or during the night), an asthma attack, or use of an inhaled or oral medication to help breathing.[@b25-copd-11-1097]

Measurements
------------

BMI was calculated as weight (kg)/height (m)[@b2-copd-11-1097]. Spirometry was performed using a computerized Fleisch pneumotach (Hewlett Packard, Palo Alto, CA, USA) in 1993 and an Easy-One spirometer (NDD, Zürich CH, Switzerland) in 2013. The current spirometry guidelines at the time were followed.[@b26-copd-11-1097],[@b27-copd-11-1097] Baseline lung function was compared with Caucasian predicted values from the US National Health And Nutrition Examination Survey.[@b9-copd-11-1097] The rate of LFD was measured as declines in FEV~1~ (mL/year) (ΔFEV~1~) and FVC (ΔFVC) divided by the time interval (in years) between tests in 262 subjects who attended both the surveys in Melbourne.

Statistical analysis
--------------------

We compared the prevalences of respiratory symptoms, asthma, and allergies between males and females and between ECRHS I and III using logistic regression with robust errors estimated from generalized estimating equations. Sex, survey time (categorical), and an interaction between them were included as predictors in the model. Multiple linear regression was used to estimate associations between risk factors and rate of LFD separately for males and females. The following covariates were considered: height, current smoking, pack-years in 2013, maternal smoking, asthma, inhaled or oral medication in 1993, and ΔBMI. The stepwise algorithm entered a covariate into the model if *P*\<0.05 and removed it if *P*\>0.1. At each step, all eligible variables were considered for removal and entry. Results are presented for the most parsimonious models as regression coefficients with 95% confidence intervals. Statistical analyses were conducted in SPSS (version 20, IBM Corp, Armonk, NY, USA) or Stata version 14 (Stata Corporation, College Station, TX, USA).

Results
=======

Symptoms and allergies
----------------------

The prevalence (and 95% confidence intervals) of respiratory symptoms and allergies by sex over time are shown in [Table 1](#t1-copd-11-1097){ref-type="table"} for 318 participants who completed questionnaires on two occasions. There was no evidence that the effect of time on symptom prevalence differed by sex (no interactions were statistically significant). In both surveys, nocturnal cough (*P*=0.006) and skin allergies (*P*=0.049) were significantly more prevalent in females than males. Conversely, morning sputum was slightly more prevalent in males than females (*P*=0.008). The prevalence of most symptoms had either remained fairly constant or decreased over 20 years, significantly so for wheeze (*P*\<0.001) and skin allergies (*P*=0.004). However, prevalence for shortness of breath after activity had increased (*P*=0.018).

Compared with participants in both surveys, those who only participated in 1993 were slightly younger (33.5 vs 35.5 years, *P*\<0.001) and significantly more likely to report wheeze (*P*=0.014), nocturnal cough (*P*=0.033), morning sputum (*P*=0.02), or nasal allergies (*P*=0.049). There were no significant differences between those who continued to participate and drop outs in sex, shortness of breath after activity, current asthma, skin allergies, inhaled or oral medications, or smoking in 1993 (data not shown).

Lung function
-------------

The baseline and follow-up characteristics of the 262 subjects who completed spirometry are described by sex in [Table 2](#t2-copd-11-1097){ref-type="table"}. By the time of resurvey in 2013, the subjects were almost 20 years older; had gained, on average, 7--8 kg in weight; mean BMI had increased by 2.2 kg/m^2^ in males and 3.2 kg/m^2^ in females. Lung function had declined; overall mean FEV~1~ declined by 23.1 (±17.1) and FVC by 22.9 (±20.2) mL/year. Mean ΔFEV~1~ and ΔFVC in males and females are given in [Table 2](#t2-copd-11-1097){ref-type="table"}. The differences between males and females in weight, BMI in 1993, lung function on both occasions, and ΔBMI were statistically significant. By 2013, 16 (6.0%) participants had Global initiative for Obstructive Lung Disease (GOLD) Stage II or greater COPD (FEV~1~/FVC \<70% and FEV~1~ \<80% predicted).

Predictors of lung function decline
-----------------------------------

Age and baseline FEV~1~ were associated with the decline in FEV~1~ in both sexes ([Table 3](#t3-copd-11-1097){ref-type="table"}). However, maternal smoking and height were also independent predictors in males. Pack-years smoked and change in BMI were independent predictors in females. Current smoking in 2013, asthma and inhaled or oral medication in 1993 were not related to ΔFEV~1~ in either sex. However, mean ΔFEV~1~ was significantly more rapid among those who continued smoking (32.7±20.9 mL/year) compared with those who quit between 1993 and 2013 (17.1±23.5 mL/year, *P*=0.02). The relationship between baseline smoking status and mean ΔFEV~1~ is shown in [Figure 1](#f1-copd-11-1097){ref-type="fig"}. Although ΔFEV~1~ was greater in females than males who were smokers in 1993, the confidence intervals were wide and overlapped. Nonetheless, the effect of pack-years smoked by 2013 was greatest in females.

Furthermore, age, baseline FVC, height, and ΔBMI were independent predictors of ΔFVC in both sexes ([Table 4](#t4-copd-11-1097){ref-type="table"}). Smoking in 2013, pack-years smoked, maternal smoking, asthma, inhaled or oral medication in 1993 were not related to ΔFVC in either sex. Nor was there any significant difference in ΔFVC between those who continued to smoke or quit. The relationship between baseline BMI and mean ΔFVC is shown in [Figure 2](#f2-copd-11-1097){ref-type="fig"}. The effect was greatest in females who were already obese at baseline.

Discussion
==========

This 20-year follow-up of a cohort of Melbourne adults has found that prevalence of most respiratory symptoms had either remained relatively stable or decreased (significantly so for wheeze). The exception was shortness of breath after activity, which had increased. Shortness of breath is not specific to respiratory disease and may be due to cardiac disease or simply physical deconditioning in this age group. The prevalence of wheeze was comparable, but the prevalence of sputum was less compared with adults of similar age in Busselton,[@b6-copd-11-1097] or rural Canadian adults who were 10 years younger on average.[@b5-copd-11-1097]

The rate of LFD (both ΔFEV~1~ and ΔFVC) was slightly higher in females than males. Decline in FEV~1~ was associated with age and baseline FEV~1~ in both sexes, as well as height and maternal smoking in males, and pack-years and ΔBMI in females. Age, baseline lung function, and ΔBMI were associated with decline in FVC in both sexes. However, the influence of baseline lung function was not consistent with the "horse-racing effect" in COPD, in which those with the lowest lung function are expected to have the most rapid rate of decline.[@b11-copd-11-1097],[@b28-copd-11-1097] This might be because we recruited a community-based sample, in which relatively few individuals met spirometric criteria for COPD.

Change in BMI was slightly higher in females compared with males, which could be attributed to hormonal changes during menopause. Although we did not collect data on menopause, the mean age at natural menopause is 48.8 years internationally and 50% of Australian females reach menopause by the age of 52.[@b29-copd-11-1097] It is well known that male pattern obesity (the so-called apple shape) and metabolic syndrome become more common in postmenopausal females.[@b30-copd-11-1097] Our female participants gained more weight and had a significantly greater increase in BMI than males. Furthermore, we found that decline in FVC in obese females was higher than obese males. Male pattern obesity would be expected to cause greater diaphragmatic splinting and lung restriction than female pattern obesity (pear shape). New-onset asthma and respiratory symptoms increased in females not on exogenous hormonal therapy on becoming postmenopausal in a longitudinal population-based study in Northern Europe.[@b31-copd-11-1097]

Tobacco smoking is the major risk factor for the development of airflow limitation and COPD,[@b11-copd-11-1097],[@b32-copd-11-1097] and a previous study has suggested that smoking females are at greater risk than males.[@b33-copd-11-1097] Possible mechanisms would include smaller airways, sex differences in smoke metabolism, immunological, or hormonal differences.[@b33-copd-11-1097] We found that female current smokers had higher mean ΔFEV~1~ than male current smokers, but were unable to examine biological mechanisms. It is possible that our inability to detect a significant effect of current smoking in males was because they had smoked less on average and/or limited statistical power. However, our overall findings confirmed the importance of smoking cessation to preserve lung function. Cumulative pack-years smoked appeared more important than current smoking, perhaps due to survivor effects. Although the prevalence of smoking has fallen over the last 25 years in Australia, young females are now just as likely to be current smokers as young males.[@b34-copd-11-1097] Our findings provide some additional evidence for targeted smoking cessation campaigns directed toward females. This would also help reduce exposures in utero and during early childhood. The effect of maternal smoking appeared greatest in adult males consistent with some previous studies.[@b35-copd-11-1097]

Strengths and limitations
-------------------------

The ECRHS has the strengths of following a standardized protocol with validated questionnaires and careful attention to the quality of lung function data. However, similar to all cohort studies, there has been substantial attrition over 20 years. While the original sample was population based, the remaining subjects might not be fully representative of middle-aged adults in Melbourne. Specifically, those who dropped out were slightly younger and perhaps surprisingly more likely to report respiratory symptoms. So, the prevalence of some symptoms 20 years later was likely to be underestimated. Unfortunately, different types of spirometers were used in each survey. The pneumotach used a differential pressure transducer, whereas the EasyOne has an ultrasonic flow transducer. We were unable to find a direct head-to-head comparison, but the choice of spirometer can affect the sample size required for clinical studies with endpoints such as FEV~1~.[@b36-copd-11-1097] This local analysis has limited statistical power, particularly to examine less common risk factors and exposures. The final pooled and cleaned lung function data from all centers are awaited, which will be the subject of a planned international analysis.

Conclusion
==========

Obesity and smoking put females at higher risk of LFD than males. In Australia, there are already health promotion campaigns around healthy eating, physical activity, and smoking cessation. Our findings suggest that these could, in part, be retargeted toward females to reduce the future risk of chronic lung diseases. We would encourage clinicians to ask middle-aged patients presenting with respiratory symptoms about early life factors, as well as taking a full smoking history and measuring their height, weight, and lung function.
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###### 

The number (%) of participants with respiratory symptoms or allergies by sex and survey

  Respiratory symptom or allergy   Males (n=147)   Females (n=171)   *P*-value comparing surveys[a](#tfn1-copd-11-1097){ref-type="table-fn"}   *P*-value comparing sex[b](#tfn2-copd-11-1097){ref-type="table-fn"}   *P*-value for sex × time interaction[c](#tfn3-copd-11-1097){ref-type="table-fn"}           
  -------------------------------- --------------- ----------------- ------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------- -------
  Wheeze                           53 (36%)        39 (27%)          75 (44%)                                                                  46 (27%)                                                              \<0.001                                                                            0.385   0.250
  SOB after activity               45 (31%)        59 (40%)          64 (37%)                                                                  73 (43%)                                                              0.018                                                                              0.262   0.504
  Nocturnal cough                  39 (27%)        38 (26%)          70 (41%)                                                                  58 (34%)                                                              0.289                                                                              0.006   0.405
  Morning sputum                   24 (16%)        17 (12%)          11 (6%)                                                                   11 (7%)                                                               0.405                                                                              0.008   0.385
  Nasal allergies                  64 (44%)        74 (50%)          91 (53%)                                                                  95 (56%)                                                              0.061                                                                              0.132   0.408
  Skin allergies                   66 (45%)        53 (36%)          92 (54%)                                                                  78 (46%)                                                              0.004                                                                              0.049   0.814
  Current asthma                   32 (22%)        36 (24%)          42 (25%)                                                                  48 (28%)                                                              0.105                                                                              0.474   0.881

**Notes:**

*P*-value calculated from logistic regression (with GEEs) -- marginal effect of time,

*P*-value calculated from logistic regression (with GEEs) -- marginal effect of sex, and

*P*-value calculated from logistic regression (with GEEs) interaction for sex × time.

**Abbreviations:** GEE, generalized estimating equations; SOB, shortness of breath.

###### 

Baseline and follow-up characteristics of subjects who had spirometry in 1993 and 2013

                                                     Males Mean (SD) (n=130)   Females Mean (SD) (n=132)
  -------------------------------------------------- ------------------------- ----------------------------------------------------------
  **Baseline characteristics (1993)**                                          
  Age (years)                                        35.6 (5.9)                35.1 (6.4)
  Weight (kg)                                        80.3 (11.9)               64.8 (11.9)[\*](#tfn5-copd-11-1097){ref-type="table-fn"}
  BMI (kg/m^2^)                                      25.8 (2.8)                24.5 (4.1)[†](#tfn7-copd-11-1097){ref-type="table-fn"}
  FEV~1~ (L)                                         4.02 (0.7)                3.0 (0.4)[\*](#tfn5-copd-11-1097){ref-type="table-fn"}
    (% predicted)                                    94.7 (14.0)               97.0 (11.5)
  FVC (L)                                            5.25 (0.77)               3.82 (0.66)[\*](#tfn5-copd-11-1097){ref-type="table-fn"}
    (% predicted)                                    99.5 (11.5)               102.4 (13.1)
  FEV~1~/FVC (%)                                     77 (7.2)                  79 (6.8)[‡](#tfn8-copd-11-1097){ref-type="table-fn"}
  Smoking status (%)                                                           
   Never smoked                                      52.3                      56.1
   Former smoker                                     26.9                      24.2
   Current smoker                                    20.8                      19.7
  **Characteristics on follow-up (2013)**                                      
  Age (years)                                        55.4 (5.9)                55.0 (6.3)
  Age difference (years)                             19.8 (0.59)               19.8 (0.58)
  Weight (kg)                                        87.4 (16.5)               72.9 (16.3)[\*](#tfn5-copd-11-1097){ref-type="table-fn"}
  Weight difference (kg)                             7.0 (9.1)                 8.1 (9.8)
  BMI (kg/m^2^)                                      27.9 (4.4)                27.7 (5.9)
  ΔBMI 1993--2013 (kg/m^2^)                          2.2 (2.97)                3.2 (3.8)[\*\*](#tfn6-copd-11-1097){ref-type="table-fn"}
  FEV~1~(L)                                          3.61 (0.68)               2.52 (0.46)[\*](#tfn5-copd-11-1097){ref-type="table-fn"}
  FVC (L)                                            4.84 (0.8)                3.35 (0.6)[\*](#tfn5-copd-11-1097){ref-type="table-fn"}
  ΔFEV~1~ in mL/year                                 21.4 (19.4)               24.7 (14.4)
  ΔFVC in mL/year                                    21.1 (20.1)               24.7 (20.2)
  FEV~1~/FVC decline (%)                             2.2 (5.0)                 3.4 (5.4)
  Current smoker (%)                                 6.9                       7.7
  Pack-years for current smokers 2013 median (IQR)   13.6 (11.0, 35.3)         28.4 (7.8, 33.8)

**Notes:**

*P*\<0.001,

*P*=0.014,

*P*=0.004,

*P*=0.006.

**Abbreviations:** ΔBMI, change in body mass index; ΔFEV~1~, rate of decline over time in forced expiratory volume in 1 second (mL/year); ΔFVC, rate of decline over time in forced vital capacity (mL/year); IQR, interquartile range; SD, standard deviation.

###### 

Multiple regression coefficients (with 95% CI) for associations between decline in FEV~1~ and clinical characteristics

  Predictors                  Males (n=130)       Females (n=132)
  --------------------------- ------------------- -------------------
  Age (1993)                  1.2 (0.6, 1.7)      0.85 (0.5, 1.2)
  Baseline FEV~1~             13.3 (8.3, 18.3)    10.8 (5.7, 15.9)
  Maternal smoking            9.4 (2.8, 16)       NS
  Pack-years smoked by 2013   NS                  0.37 (0.07, 0.67)
  Height (1993)               −0.8 (−1.2, −0.3)   NS
  ΔBMI                        NS                  1.3 (0.7, 1.8)

**Note:** Other covariates were not included in the final model.

**Abbreviations:** ΔBMI, change in body mass index; CI, confidence interval; NS, not significant, that is, covariate were not entered in final regression model.

###### 

Multiple regression coefficients (with 95% CI) for associations between decline in FVC and clinical characteristics

  Predictors      Males (n=130)       Females (n=132)
  --------------- ------------------- -------------------
  Age (1993)      1.1 (0.6, 1.7)      1.4 (1.0, 1.8)
  Baseline FVC    10.4 (5.2, 15.7)    20.4 (15.0, 25.8)
  Height (1993)   −0.7 (−0.1, −1.3)   −0.6 (−0.1, −1.1)
  ΔBMI            2.0 (0.9, 3.1)      1.8 (1.0, 2.5)

**Note:** Other covariates were not included in the final model.

**Abbreviations:** ΔBMI, change in body mass index; CI, confidence interval.
